Headquartered in West Conshohocken, PA Fiscal year ends December NASDAQ: MDGL madrigalpharma.com
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease that can lead to cirrhosis, liver failure, liver cancer and transplantation. Its sole marketed product is Rezdiffra (resmetirom), a once-daily, oral, liver-directed thyroid hormone receptor-beta (THR-β) agonist. Rezdiffra was the first medication approved by both the FDA and the European Commission for MASH with moderate to advanced fibrosis (F2-F3). Revenue comes from Rezdiffra product sales, predominantly in the U.S., and the company pays royalties to Roche on those sales. Madrigal supports the brand with a hepatology and endocrinology field force and direct-to-consumer marketing. It is pursuing expansion into compensated MASH cirrhosis (F4c) through two trials: the ongoing Phase 3 MAESTRO-NASH OUTCOMES trial (data expected late 2027) and the planned Phase 3 MAESTRO-CSPH trial (initiation expected 1H 2027). The company is also developing pipeline candidates for MASH and building a large real-world evidence program. Updated
Madrigal is profitable: its first GAAP net income quarter after years of losses, with year-to-date Rezdiffra sales crossing $1 billion less than three years after launch. Revenue also topped estimates.
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could…
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs,…
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
The past week's most notable insider buying included a biopharmaceutical company, a pipeline company, and an industrial products maker.
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
John Paulson is among the most well-known billionaires, famous for his long-term investing returns via his hedge fund Paulson & Co. The hedge fund manager has concentrated his portfolio in interesting stocks,…
Chris MacDonald The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,…
Warren Buffett's Berkshire Hathaway has bolstered its stake in Occidental Petroleum with a huge purchase of shares. Insider buying is heating up in general.
Some of the biggest insider buying since the Thanksgiving holiday has come from repeat buyers, including Bill Ackman, who continues to build his stake in a real estate firm.
Notable insider buying in the past week included biotech and energy companies, including some that have just gone public. Also, renowned hedge fund manager Bill Ackman continues building a stake in a…
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease that can lead to cirrhosis, liver failure, liver cancer and transplantation.
The Wall Street consensus 12-month price target for MDGL is $685.22. MDGL price prediction →
